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TO THE EDITORFirst-in-Man Transseptal
Implantation of a
“Surgical-Like” Mitral
Valve Annuloplasty Device
for Functional Mitral
RegurgitationUndersized annuloplasty is an established ﬁrst-line
therapy option for functional mitral regurgitation
(MR) (1). Percutaneous direct annuloplasty as a stand-
alone therapy, as well as in combination with other
transcatheter mitral interventions, aims to reproduce
surgical annuloplasty (2).
The “ﬁrst-in-man” patient was a 69-year-old
gentleman with ischemic cardiomyopathy and
severe functional MR (effective regurgitant oriﬁce
area [EROA] 0.29 cm2; regurgitant volume [RVol]
39 ml/beat) (Figure 1, Online Video 1) admitted in New
York Heart Association (NYHA) functional class III af-
ter recurrent episodes of decompensated heart failure
in the previous 3 months. He had a clinical history of
permanent atrial ﬁbrillation, prior coronary artery
bypass grafting (patent left internal mammary artery
graft to the left anterior descending coronary artery,
left radial artery “T” graft to the right posterior
descending coronary artery). The EuroSCORE II–esti-
mated risk of operativemortalitywas 13%. After formal
heart team discussion, agreement was reached on
attempting transcatheter mitral valve repair with the
Cardioband (3) annuloplasty system (Valtech Cardio,
Or Yehuda, Israel). The annuloplasty device is deliv-
ered through a 25-F steerable transfemoral transseptal
delivery system in a supra-annular position, similarly
to what is done in surgical mitral valve repair. The
device is secured on the mitral annulus using 12 to 16
anchor elements, placed along the implant, in a
counterclockwise direction. Once the Cardioband is
completely implanted, a size adjustment tool is
used to reduce the device length under echocardiog-
raphy guidance. The intervention was performed
under general anesthesia and 2-dimensional (2D)
and real-time 3-dimensional (3D) transesophagealechocardiographic (TEE) guidance. Although ﬂuoros-
copy is fundamental for device handling, 3D echo-
cardiography efﬁciently guides the intervention,
providing the necessary information to proceed safely
and effectively. In particular, 3D echocardiography is
used to identify the commissures (Figure 1, Online
Video 2) and to obtain images of the delivery system
angulations related to the annulus, whereas 2D imag-
ing (with X-plane functionality) is mostly used to
conﬁrm proper location and to rule out leaﬂet
impingement. The transseptal puncture was per-
formed under TEE guidance aiming for an inferior
approach because this enables more accurate deploy-
ment of the Cardioband. Afterward, an extra support
0.035-inch guidewire was positioned in the upper left
pulmonary vein, and this was used to advance a pro-
prietary transseptal steerable sheath. The implant
delivery system was then advanced inside the sheath.
Using a multiple imaging modality, the ﬁrst anchoring
location was identiﬁed. Before the ﬁrst anchor de-
livery, the relative position of the delivery system to
the circumﬂex artery was checked by selective arteri-
ography of the left coronary artery. Thereafter, the ﬁrst
anchor was deployed in the anterior commissure with
the proprietary torqueable system. Echocardiography
and angiography were used to conﬁrm correct anchor
deployment. Following implant, the anchor was
released from the anchor drive, and the catheter was
advanced to the next anchor location, medial and
posterior relative to the ﬁrst one, along the posterior
annulus. Commissure-to-commissure anchor deploy-
ment required a total of 45 min (Figure 2). The delivery
system was then retrieved in exchange for a pro-
prietary size adjustment tool, designed to cinch the
implanted device by applying tension on a wire acti-
vated by a proprietary adjustment mechanism.
Following adjustments under TEE guidance, MR was
reduced from severe to mild (Figure 1, Online Videos 1
and 2), with a corresponding change in EROA from
0.29 cm2 to 0.09 cm2. The septolateral dimension
was reduced from 39 mm to 30 mm (Figure 1). This
amount of annular remodeling is similar to what is
usually achieved with undersized surgical annulo-
plasty. The Cardioband was then disconnected from
the size adjustment catheter, and the transseptal
steerable sheath was retrieved. Venous access was
secured with a “ﬁgure of 8” cutaneous suture. The
patient was discharged uneventfully 3 days after the
intervention. At 1-year follow-up, the patient is in
FIGURE 1 Baseline and Post-Adjustment Echocardiography
Baseline (A and C) and post-adjustment (B and D) echocardiography. Following Cardioband implant, but before size adjustment, mitral regurgitation (MR) is
still severe (A) (Online Video 1); the intercommissural and the septolateral diameters are 43 mm and 39 mm, respectively (C). Following Cardioband size
adjustment (Online Video 2), residual MR is minimal (B), and the annulus dimensions are reduced to 34 mm and 30 mm for the intercommissural and the
septolateral diameter, respectively (D) (Online Video 3).
FIGURE 2 Intraprocedural Multimodality Imaging During Cardioband Implant
(A to C) Fluoroscopy; (D to F) 3-dimensional (3D) echocardiography “surgical” view. (A and D) Deployment of the ﬁrst anchor in the ante-
rolateral commissure; (B and E) complete deployment of the implant before size adjustment; (C and F) annular reduction after size adjustment,
posterior annular cinching is evident on both ﬂuoroscopy and 3D echocardiography.
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(assessed by an independent core-lab) has remained
mild (Figure 1, Online Video 3) with an EROA ¼
0.09 cm2 and RVol ¼ 12 ml/beat.
Transcatheter therapies for treatment of cardiac
diseases are increasingly being adopted, particularly
for high-risk surgical patients. This case demonstrates
the feasibility of percutaneous transseptal delivery of
a “surgical-like” adjustable posterior annuloplasty
Dacron band. Cardioband implantation was associ-
ated with substantial reduction of the septolateral
annular dimension, to an extent comparable to that
obtained by surgical annuloplasty. Clinical studies are
warranted to appraise its risk–beneﬁt balance in ab-
solute terms and in comparison, or in combination,
with other transcatheter mitral valve repair strategies.*Francesco Maisano, MD
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APPENDIX For the supplemental videos, please see the online
version of this article.Experience With an
Innovative New Food
and Drug Administration
Pathway for
First-in-Human Studies
Carotid Baroreceptor Ampliﬁcation
for Resistant HypertensionIt has now been over 2 years since JACC: Car-
diovascular Interventions published the Bertog et al.
state-of-the-art review (1) “Renal Denervation for
Hypertension,” detailing the physiological rationale
for renal denervation (RDN) in resistant hyperten-
sion. Since then, interest in the ﬁeld of sympathetic
modulation soared exponentially but was quickly
brought back to earth with the publication of the
SYMPLICITY HTN-3 (Renal Denervation in Patients
With Uncontrolled Hypertension) study, the only
blinded, randomized study of RDN, which failed to
meet its pre-speciﬁed efﬁcacy endpoint (2). It is
currently unclear whether the results of SYMPLICITY-
3 were due to technically inadequate ablation,
underestimation of additional beneﬁts from study-
mediated medical therapy, or inappropriate patient
selection, or whether the initial hypothesis was in
some way ﬂawed. We believe the former issues are
likely in play and that the optimistic conclusions from
Bertog et al. (1) for RDN will ultimately hold true.
However, given the unmet need of alternative ther-
apeutic options for resistant hypertension, explora-
tion for alternative methods to modulate sympathetic
tone is warranted.
It is well known that the carotid baroreﬂex is an
important feedback loop for hemodynamic balance
and adrenergic tone. Carotid baroreceptors are known
to activate by pulsatile stretch rather than pressure
and the receptor response decays when stimulation
from stretch is constant, explaining why hemody-
namic changes after carotid stenting are generally
transient (3). A study of electrical baroreceptor stim-
ulation for treatment of resistant hypertension via a
surgical implant adjacent to the carotid sinus was
successful in lowering blood pressure (BP), however,
it did not meet its pre-speciﬁed procedural safety
endpoint (4). Although effective, this surgical risk
may not be acceptable for most resistant hyperten-
sive patients. Combining knowledge of baroreceptor
physiology with known pressure–strain relationships
for pressurized tubular structures, we hypothesized
that certain geometric changes of the carotid bulb
